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one of the two cDNA strands: a 5’ EST is obtained whenIntroduction 
the beginning portion of a cDNA is sequenced, whereas
a 3’ EST is obtained when the ending portion of a cDNA
The Debate is sequenced. 9 ESTs thus represent short DNA sequences,
the majority of which encode part of a gene, but rarely a
he patentability of human genetic material has full-length gene. As will be discussed in greater detailT given rise to considerable debate around the below, they are generally only useful to researchers as
world. 1 As Kevles notes, ‘‘[o]ne of the most controversial tools to identify the full-length gene, and rarely provide
issues in biotechnology in the Unites States and Europe information about the function or location of the gene.
has been the patenting of human DNA sequences and
human genes’’. 2 A number of academics and organiza-
Focus of this Article tions have written on the issue, and arguments both for
and against have covered a broad range of concerns of an A number of patent applications seeking protection
economic, social, medical, scientific and ethical nature. over DNA fragments, in particular ESTs, have been filed
Patents have been issued on human genetic mate- with the Canadian Intellectual Property Office (CIPO),
rial in most jurisdictions. 3 Applicants have sought protec- which is currently faced with the difficult task of deter-
tion for DNA fragments (nucleotide sequences that do mining whether such products are patentable subject-
not encode full-length genes) including promoter matter and whether they satisfy the requirements under
sequences, enhancer sequences, individual exons, com- the Patent Act. 10 Whatever CIPO ultimately decides, we
plimentary DNA (cDNA), expressed sequences tags could expect litigation to arise, calling upon the courts to
(ESTs) and single nucleotide polymorphisms (SNPs). 4 clarify the issue. 11
Patent protection has also been sought and granted for In the United States, utility is the patentability
full-length gene sequences, synthetic and mutant DNA requirement that has received the most scholarly atten-
and gene sequences, amino acid sequences, cloning and tion in the context of patenting of biotechnological
expression vectors, methods of transforming genes, and inventions, because of the debate surrounding the pat-
recombinant DNA.5 The majority of these patents have entability of ESTs. 12 Both courts and the Patents and
been issued by American, European, and Japanese patent Trademarks Office (USPTO) have struggled to address
offices. 6 criticisms both for and against their patentability. It is
The technical debate as to whether human genetic still not clear exactly how the USPTO treats applications
material meets the requirements for patentability under for EST patents. 13
the law has mainly focused on DNA sequences that do The following discussion will examine the utility
not encode full-length genes, such as ESTs. requirement for patentability in the context of EST pat-
ents. Part I will provide background information
What are ESTs? regarding the utility requirement under patent law and
Double-stranded human DNA contains sequences will explain why it has been difficult to apply to ESTs.
which code for genes. When genes are expressed, they Part II will briefly examine how other jurisdictions, in
produce proteins. During a process called transcription, particular the United States, have addressed the difficul-
the parts of DNA that encode genes are copied into ties associated with applying the current utility require-
mRNA. The mRNA present in cells at any given time ment to biological materials, in particular ESTs. Part III
presents a picture of which genes are being expressed. 7 will look at how Canadian courts have interpreted and
Using an enzyme called reverse transcriptase, researchers applied the utility requirement for patentability, and will
are able to produce a complimentary and more stable suggest that ESTs have sufficient value to the scientific
copy of the mRNA called cDNA.8 ESTs are produced by community to satisfy this requirement. In addition, it
sequencing a small number of nucleotides at the end of will examine how the doctrine of sound prediction may
†B.Sc. Biology (Ottawa), B.C.L./LL.B. (McGill), LL.M. Candidate (Law & Technology) (Ottawa). E-mail: nbellefe@hotmail.com. The author wishes to thank

































































74 Canadian Journal of Law and Technology
allow patent protection to be extended beyond the Difficulties in Applying the Utility
simple EST nucleotide sequence. This article will con- Requirement to ESTs 
clude by suggesting two reasons why the utility criterion
In most jurisdictions, patent legislation has not beenfor patentability has proven difficult to apply to human
significantly amended to reflect advancements in bio-genetic materials.
technology. As explained in the Government of OntarioThe patenting of human genetic materials,
report, Genetics, Testing & Gene Patenting: Chartingincluding ESTs, raises a number of concerns apart from
New Territory in Healthcare, ‘‘the current patent systemthe question of whether they meet the utility require-
in Canada [is] not. . .designed to address questions ofment under patent legislation. Not only are there legal
DNA patenting and the commercialization of theconcerns in terms of whether such ‘‘inventions’’ are pat-
human genome’’. 27 In the Harvard Mouse case, theentable subject-matter and whether they satisfy the
majority of the Supreme Court of Canada stated that therequirements of novelty and non-obviousness, but there
Patent Act is ‘‘ill-equipped’’ to deal with the patenting ofare also important moral concerns. 14 While all of these
higher life forms. 28issues are clearly related and not completely separable,
an examination of their intersection is beyond the scope
The Agreement on Trade-Related Aspects of Intel-of this article.
lectual Property Rights requires that ‘‘patent laws [be]
applied without discrimination on the basis of tech-
nology’’. 29 This has the status of an international norm.30
Part I: Utility as a Patentability Despite the fact that patent legislation is poorly designed
to address innovation in the field of biotechnology, suchRequirement 
inventions must be considered within the same patent
regime as all other inventions. 31 Courts and patent
The Utility Requirement offices around the world have therefore been faced with
the difficult task of interpreting their legislative provi-n Canada, an invention is defined as ‘‘any new and
sions and developing interpretive guidelines to addressI useful art, process, machine, manufacture or composi-
the issues raised by biotechnological inventions. 32tion of matter, or any new and useful improvement in
any art, process, machine, manufacture or composition
Because of exceptional advancements in DNAof matter’’. 15 To meet the utility requirement, an inven-
sequencing techniques that have occurred over the lasttion must do what the patent claims say it can do. 16
10 years, ‘‘more DNA sequences have become availableAccording to the CIPO Manual of Patent Office Practice
without a concomitant understanding of their func-(MOPOP), the invention must be ‘‘operative, controllable
tion’’. 33 DNA sequences that arise from these methodsand reproducible’’. 17 Patent legislation in the United
often represent short stretches of DNA, such as ESTs.States18 and Australia 19 similarly require that an inven-
Most ESTs do not provide scientifically useful informa-tion be ‘‘useful’’ to be patentable.
tion regarding the identity or function of the full-length
The European Patent Convention, at article 52, sets gene. 34 Rather, ESTs are generally considered ‘‘weak and
out the requirements that must be met for a patent to be nonspecific tools for further research’’ that are generally
issued: ‘‘Patents shall be granted for any inventions only useful as probes or chromosomal markers. 35 A
which are susceptible of industrial application, which are probe is a ‘‘DNA sequence that is used to detect the
new and which involve an inventive step’’. 20 It further presence of a complementary sequence by hybridization
states that ‘‘an invention shall be considered as suscep- with a nucleic acid sample’’. 36 A chromosomal marker is
tible of industrial application if it can be made or used in defined as ‘‘[a] distinct sequence found on a chromo-
any kind of industry, including agriculture’’. 21 Section some that helps identify a particular area of it’’. 37 While
29(1) of the Japan Patent Law reads ‘‘any person who has ESTs can be used to isolate the full-length gene, which
made an invention which is industrially applicable may can then be sequenced and characterized to identify its
obtain a patent therefor. . ..’’. 22 ‘‘The word ‘industry’ is function, it is the full-length gene which tends to be
interpreted in a broad sense, including mining, agricul- viewed as the subject of interest and value, not the EST.
ture, fishery, transportation, telecommunications, etc., as
well as manufacturing’’. 23 The application of the utility requirement to ESTs is
According to the Nuffield Council on Bioethics problematic because, as Lech explains, any DNA
report entitled The Ethics of Patenting DNA, the expres- sequence can be used to identify the chromosome from
sion ‘‘susceptible of industrial application’’ is broader which it originates or to locate the gene to which it
than the term ‘‘utility’’. 24 The report suggests that, in relates. 38 Similarly, all ESTs can be used as probes or
practice because industrial applicability has been con- markers to locate the full-length gene, except perhaps for
strued narrowly, the two standards are analogous. 25 This, those that are short and only encode a polyA or polyT
however, does not appear to be a unanimous position, sequence (short sequence from the 3’ end of the EST). 39
one source suggesting that, in fact, utility is broader than Thus, use as probes and markers is not specific to ESTs,
































































ESTs under Canadian Patent Law: Useful or Not? 75
Occasionally, a full-length gene will be encom- evenly. 50 In 1991, the National Institutes of Health filed
passed within a single EST, or the DNA sequence of the patent applications for approximately 2,700 partial DNA
EST will reveal an important motif or domain, which sequences, seeking protection not only for the EST
can allow the function of the gene and/or protein to be sequences, but also for the full-length gene sequences
predicted. 40 In addition, ESTs can have very specific uses. and the proteins derived from these genes. 51 On the
As explained in the CBAC Report: ‘‘The utilities of basis of Brenner v. Manson, the applications were denied
nucleotide sequences patented to date include their role as the DNA sequences in question were considered mere
in gene regulation, encoding for therapeutic proteins, research tools that would not satisfy the utility require-
diagnostic probes, receptors used for identifying molec- ment. 52
ular targets for therapeutic drug development, immu-
The USPTO, in 1995, issued examination guide-nogens, and gene replacement therapies ’’. 41 DNA
lines which imposed a more generous standard forsequences with such functions usually satisfy the utility
assessing utility. These guidelines required ‘‘crediblerequirement since they have a specific use apart from
utility’’, which could be satisfied if ‘‘the assertion ofthat of the full-length gene.
utility was believable to a person of ordinary skill in the
This leads to the question of what type of utility is art based on the totality of evidence and reasoning pro-
necessary for ESTs to satisfy the requirement under vided’’. 53 The guidelines were viewed as a return to the
patent legislation. Is the scientific value of research tools de minimis standard. 54 They did not, however, resolve all
sufficient to meet the utility requirement under the law? of the issues associated with EST patentability. 55
In 1997, the USPTO announced that from then on
it would be granting patents for ESTs, as their utility asPart II: Response in Other Jurisdic-
probes for locating the corresponding full-length genetions was sufficient to meet the requirement under the new
guidelines. 56 It did specify, however, that the patent
United States would not cover the full-length gene unless the EST
encompassed the entire gene sequence. 57 This decisionost of the debate regarding the patentability of
was highly controversial. Only two months later, theM human genetic material, in particular ESTs, has
USPTO revised its position, stating that ‘‘usefulness as ataken place in the United States. To understand how the
probe alone [will] not qualify an EST as patent-utility requirement applies to DNA patents, it is impor-
able. . .[The] inventor must have some knowledge of thetant to examine how the interpretation of the require-
function or utility of the target gene for an EST as ament has changed over time.
probe to satisfy the legal requirements for patenting’’. 58
Prior to 1966, an invention was considered useful if Furthermore, ‘‘patent applicants must demonstrate a
it was not ‘‘frivolous or injurious to the well-being, good more ‘substantial, real-world utility; not some throwaway
policy, or sound morals of society’’. 42 The utility require- utility’’’. 59 Thus, a large number of ESTs would not meet
ment was, at this time, described as a de minimis stan- the requirement. 60 Based on the Eli Lilly decision of
dard, as ‘‘it [was] seldom a bar to the issue of a given 1997, the USPTO ‘‘refused to grant claims on any nucle-
patent. . .[and] all that [was] required [was] a showing that otide sequence other than those disclosed in the applica-
the claimed invention [had] some practical, if attenuated, tion even if the type of gene was identified’’. 61
application or use’’. 43
In 2001, the USPTO issued revised utility guide-In the 1966 decision of Brenner v. Manson, the
lines, according to which an applicant must ‘‘assert aUnited States Supreme Court replaced the de minimis
specific and substantial utility that a person of ordinarystandard for utility with a more demanding require-
skill in the art to which the invention pertains wouldment. 44 It found that, to be patentable, an invention had
consider credible’’. 62 A ‘‘specific’’ utility is one that is notto have ‘‘substantial utility. . .[providing a] specific benefit
general in nature, but applies to the particular subject-in its currently available form’’. 45 The Court added that
matter claimed,63 whereas, a ‘‘substantial’’ utility requiresan invention was not patentable if it was ‘‘only useful in
a real world use (an immediate benefit without the needthe sense that it may be an object of scientific
to conduct further research). 64 ‘‘Credible’’ requires thatresearch’’. 46 It also noted that ‘‘a patent is not a hunting
the utility be ‘‘believable to a person of ordinary skill inlicense. It is not a reward for the search, but compensa-
the art, based on the totality of evidence and reasoningtion for its successful conclusion’’. 47
provided’’. 65 These guidelines have been incorporated
In the 1980 decision of Diamond v. Chakrabarty, into the USPTO, Manual of Patent Examining Proce-
the United States Supreme Court adopted a very broad dure. 66
definition of what constitutes patentable subject-matter,
stating that ‘‘anything under the sun that is made by This revised utility requirement represents a return
man is eligible for patenting’’. 48 Not long after, the to the Brenner v. Manson standard. 67 A DNA sequence
USPTO started issuing patents on DNA sequences. 49 that is useful only as a gene probe or chromosomal
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A mere nucleic acid sequence without an indication of aticular gene or chromosome target is also identified. 68 A
function is not a patentable invention . . . In cases where aDNA fragment will have substantial utility where it
sequence or partial sequence of a gene is used to produce aallows genes linked to a particular disease to be identi- protein or a part of a protein, it is necessary to specify which
fied, but not where ‘‘it is only useful for studying its own protein or part of a protein is produced and what function
this protein or part of a protein performs. Alternatively,properties’’. 69 The use of ESTs as probes or markers will
when a nucleotide sequence is not used to produce a pro-always be credible, because nucleotide sequences are
tein or part of a protein, the function to be indicated couldroutinely used for such purposes. 70 be that the sequence exhibits a certain transcription pro-
moter activity [for example]. 82Thus, in the United States, certain ESTs are patent-
able. 71 According to Demaine & Fellmeth, the USPTO It does not appear, based on the above passage, that
‘‘now routinely grants, and federal courts consistently specific, substantial and credible utility is required for
uphold, patents on newly discovered. . .DNA frag- DNA patents. It is worth noting that the EU Biotech-
ments’’. 72 While quite a few patents were issued for ESTs nology Directive requires that ‘‘a patent applicant [must]
belonging to certain gene families prior to the revised disclose the industrial application of a sequence or par-
utility guidelines, it is not clear how many have been tial sequence of a gene’’. 83
granted by the USPTO since the revised guidelines have The situation in Australia is also unclear. Accordingbeen in force. 73 According to Human Genome Project to the Australian Patents for Biological Inventions factInformation online, the USPTO has issued only ‘‘a few sheet, a claimed DNA sequence must have a specificpatents for gene fragments’’. 74 utility: ‘‘[an applicant] must describe a specific use for the
biological material. . .[and] if the invention relates to aA recent Federal Circuit decision has upheld the
gene, the specification must disclose a specific use for therevised utility guidelines. In In re Fisher, the applicant
gene such as its use in the diagnosis or treatment of asought patent protection for 5 ESTs that encoded pro-
specific disease or its use in a specific enzymatic reactiontein fragments in maize plants. 75 While the structure and
or industrial process’’. 84 Despite the Australian Lawfunction of the full-length genes and proteins were
Reform Commission’s recommendation, in 2004, thatunknown, the applicant argued that this was irrelevant,
Australia adopt the United States’ approach, to date, itsince the ESTs were useful as research tools, and these
does not appear that such a standard is being applied byuses were distinct from the function of the encoded gene
the Australian patent office. 85or protein. 76 The Court found that the ESTs did not
meet the requirement under the new utility guidelines.
They did not have specific utility, because the utility
claimed applied to a broad class of invention (all ESTs
Part III: Utility Requirement inand not the specific ESTs that the applicant
‘‘invented’’). 77 The ESTs did not have substantial utility, Canada 
as set out in Brenner v. Manson, because they did not
anada has not yet taken a position as to how it willprovide an immediate benefit to the public in their avail- C address the patentability of ESTs, and in particularable form. Rather, further research would be necessary to
the question of utility. CIPO has been called upon toconfirm their ‘‘real world use’’. 78
develop interpretive guidelines in this respect, but has
not yet done so. 86 An examination of how the utility
requirement has evolved over the last century may pro-Other Jurisdictions 
vide partial answers.
A number of other jurisdictions, including the
United Kingdom, New Zealand and Japan, have
endorsed and implemented the current United States’ Utility is an Easy Test to Meet 
approach, according to which an invention must have
In Canada, the utility requirement is easily met. Inspecific, substantial and credible utility. 79
1981, the Supreme Court of Canada adopted the lan-
It is not clear whether this approach has been guage of Halsbury’s Laws of England: ‘‘[non-useful]
adopted by the European Patent Office (EPO). Although means ‘that the invention will not work, either in the
the Guidelines for Examination in the European Patent sense that it will not operate at all or, more broadly, that
Office (EPO Examination Guidelines) 80 do not explicitly it will not do what the specification promises that it will
require that an invention disclose a specific, substantial do’’. 87 A number of older cases also suggest that the
and credible utility to be considered ‘‘susceptible of utility requirement is not onerous. 88 For example, a 1928
industrial application’’, according to the Examination Exchequer Court decision found that ‘‘a definite amount
Guidelines for Patent Applications relating to Biotechno- of utility is not required by law to sustain an invention; a
logical Inventions in the UK Patent Office, to date, such slight amount of utility is sufficient’’. 89 The MOPOP
an approach has been followed by the EPO.81 With states that while an invention must have some purpose,
respect to genetic sequences, the EPO Examination it need not have any particular purpose unless such a
































































ESTs under Canadian Patent Law: Useful or Not? 77
benefit. Utility, as predicated of inventions, means indus-Interpretation and Application of the
trial value’’. 99 Applying this test to the case at hand, theUtility Requirement by Canadian Courts 
Court found that the invention lacked utility ‘‘because itUtility may be an easy test to meet, but what it
[was] inoperable for the purpose for which it wasmeans for an invention to be useful, under current
designed’’. 100 In the Court’s opinion, it was not reason-patent law, is uncertain. Canadian courts have been
able to believe that a worker competent in the art,inconsistent in their discussions on utility, using such
would, at the date of the specification, use the inventionexpressions as ‘‘ industrial value’’ and ‘‘commercial
as described. 101 In fact, the invention in question hadutility’’ without defining them. Because ESTs are often
never gone into use. The Court, in this case, appears todescribed as mere research tools that have little or no
have adopted a fairly low standard for utility.commercial value, the interpretation of utility will deter-
mine whether they satisfy the utility requirement for These two decisions, both by Maclean P. of the
patentability. For this reason, it is worth briefly reviewing Exchequer Court of Canada, appear inconsistent.
some of the cases in which Canadian courts have inter- Whereas the Court, in Prentice, found that the utility
preted and applied the utility requirement. requirement for patentability required commercial
utility, in Northern Electric, it interpreted utility asIn Re Application of Abitibi Co. [Abitibi], the appli-
requiring industrial value. It is unclear whether thecant sought a patent for a mixed fungal yeast culture
Court applied the same standard while simply usingsystem that could be used to digest effluent from wood
different terminology, or whether it applied two dif-pulp mills. 91 The Patent Appeal Board and Commis-
ferent standards for assessing utility, and if so, on whatsioner of Patents, in considering whether the patenta-
basis.bility requirements were met, stated that an invention
could not be ‘‘a mere laboratory curiosity whose only In Re Application No. 003,389 of N.V. Organon
possible claim to utility is as starting material for further [Organon], the Patent Appeal Board was called upon to
research’’. 92 The Board seems to have adopted the determine whether a patent claiming a method of patho-
Brenner v. Manson standard according to which mere logical diagnosis satisfied the definition of invention
research tools are unpatentable. The MOPOP was subse- under s. 2(d) of the Patent Act, and more specifically
quently amended to prohibit claims to mere research whether it was a useful art or process. 102 The Board
tools, requiring that inventions have industrial value. 93 found that it was, since it was ‘‘inherently beneficial to
No other Canadian case has considered, whether an the  pub l i c . . . [ and  had ]  u t i l i t y  in  p r a c t i c a l
invention useful only as a research tool, meets the utility affairs. . .[and]commercial applications’’. 103 Because the
requirement under patent legislation. Board did not address the utility requirement specifi-
cally, but rather considered whether the invention was aAlthough the Abitibi decision has not been over-
‘‘useful art or process’’, it is unclear whether its findingsturned, the short passage on utility has been cited only
are relevant to the question of utility, or whether they areonce by Canadian courts in over 20 years. Justice Binnie,
relevant to whether an invention is patentable subject-dissenting in the Supreme Court of Canada decision of
matter.Harvard Mouse, referred to the above passage in the
context of his discussion on patentable subject-matter, In the 1981 Supreme Court of Canada decision of
and without commenting on it. 94 The MOPOP has been Consolboard Inc. v. MacMillan Bloedel (Saskatchewan)
amended and no longer prohibits claims on research Ltd. [Consolboard], Dickson J., speaking to the validity of
tools. 95 On this basis, I would suggest that Canadian two patents, one for wafers and the other for a
patent law has not adopted the reasoning in Brenner v. waferboard, adopted Halsbury’s Laws of England
Manson, and that research tools are not unpatentable, according to which ‘‘the practical usefulness of the inven-
per se, for lack of utility. tion does not matter, nor does its commercial utility,
unless the specification promises commercial utility, norIn 1928, in the case of Prentice v. Dominion Rubber
does it matter whether the invention is of any real ben-Co. [Prentice], the Exchequer Court considered the
efit to the public, or particularly suitable for the purposesvalidity of a patent claiming an improvement in inter-
suggested’’. 104 As the issue in this case was whether thelocking fas tener construct ion .  I t  found that
statutory requirement to fully describe the invention in‘‘[c]ommercial utility is the very essence of a patent; a
the specification had been met, the Court did not applyfavourable reception by the purchasing public affords
the test for utility as explained in Halsbury’s Laws ofstrong evidence of that degree of utility required by
England. As such, the binding nature of the Court’s brieflaw’’. 96 The Court found that the commercial adoption
discussion on utility is uncertain. 105of the invention provided sufficient proof of its utility. 97
In the 1939 decision of Northern Electric Co. v. In 1989, in Pioneer Hi Bred Ltd. v. Canada (Com-
Brown’s Theatres Ltd. [Northern Electric], the Exchequer missioner of Patents) [Pioneer], the Supreme Court was
Court considered the validity of a patent claiming ‘‘an faced with a patent claiming a new soybean variety
invention for the control of electric currents by and in developed from cross-breeding. 106 The Court stated that
accordance with variations of light’’. 98 It stated that ‘‘[a]n ‘‘all inventions are not necessarily patentable, even if they
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industrial result, and are commercially useful. . ..’’ 107 The General Observations Based on the Cases
Court referred to the patentability requirements to Examined Above 
explain that even if these requirements are met, failure to
comply with the disclosure requirements may render an Early Exchequer Court decisions in Prentice and
invention unpatentable. It did not make any findings as Northern Electric as well as the Patent Appeal Board
to whether the utility requirement was met in the case at decision in Organon emphasized the importance of an
hand. It is interesting to note that the Court referred to invention being beneficial to the public. 118 The Supreme
the Northern Electric decision as standing for the pro- Court in Consolboard, however, adopted Halsbury’s
position that the utility requirement will be satisfied Laws of England according to which ‘‘it does not matter
where an invention is ‘‘commercially useful’’. 108 The whether the invention is of any real benefit to the
Northern Electric decision, however, interprets the public’’. 119 Because the Court in that case did not specifi-
utility requirement as requiring ‘‘industrial value’’, and cally consider whether the utility requirement was met,
does not consider commercial utility. 109 but rather considered whether the disclosure of the
invention in the specification was sufficient, it is unclearThe Patent Appeal Board, in the 1992 decision of whether its discussion on utility is authoritative. TheRe McIntyre, considered the validity of a patent claiming MOPOP states, based on the Organon decision, that sub-‘‘an apparatus and method for evaluating a patient’s ject-matter ‘‘that does not have results beneficial to theheart function by monitoring the change in arterial pul- public’’ will not satisfy the utility requirement under s. 2sations while the patient performs a heart straining of the Patent Act. 120 It is worth noting that CIPO hasmaneuver’’. 110 The patent application had originally integrated into the MOPOP certain aspects of the Hals-been denied for lack of industrial or commercial value, bury’s Laws of England passage adopted by the Supremeon the basis that because the process claims must be Court in Consolboard, but not others. 121practiced on the body of individuals, they did not
describe an industrial process and did not result in a
Of the cases examined, only Northern Electric inter-marketable product. 111 The Patent Appeal Board consid-
preted ‘‘useful’’ under the legislation as requiring that anered whether the invention was useful:
invention have ‘‘industrial value’’. 122 Other cases do not
If diagnostic methods are to be patentable then commercial explain what it means for an invention to be useful, but
value cannot be assessed as if they are processes for pro- rather, speak of the requirement being met because of
ducing milk feedstock. The test must be that the method, the commercial utility, value or success of the invention.and its results, has value to the community to which it is
For example, in Prentice, the Exchequer Court statedaddressed; that the method be reproducible by anyone
skilled in the art; and that some economic benefit can be that ‘‘a favourable reception by the purchasing public
realized by those who practice the method. We see no affords strong evidence of that degree of utility required
reason to doubt that the method claimed in this application by law’’. 123 The Federal Court in Cochlear similarlywill not be useful to the medical community.. . .The method
found that ‘‘[t]he utility of a patent may be proven by thecan be worked on a commercial scale that is adequate and
reception received from the public’’ (i.e. its commercialreasonable under the circumstances, and which will cer-
tainly result in some form of economic benefit for the prac- success). 124 Therefore, an invention which has commer-
titioner. 112 cial success will meet the utility requirement under the
law.125Interestingly, while the patent examiner seems to
have considered whether the invention had either com-
Whereas commercial utility, value or success maymercial or industrial value, 113 the Board simply consid-
provide proof of utility, these cases do not state that anered whether it had commercial value. It did, however,
invention must meet such a standard to satisfy the utilityadopt a flexible test for determining whether the utility
requirement under the law. The MOPOP previouslyrequirement is met, according to which an invention
required industrial value for an invention to be consid-will have commercial value if it ‘‘has value to the com-
ered useful. 126 This, however, has changed, and the sec-munity to which it is addressed’’. 114
tion on utility no longer explicitly requires industrial
The Trial Division of the Federal Court, in the 1995 value. 127 In fact, it does not require commercial value or
decision of Cochlear Corp. v. Cosem Neurostim Ltée commercial utility either. Rather, it simply states, on the
[Cochlear], assessed the validity of a patent claiming an basis of the decision in Consolboard, that an invention
‘‘implantable tissue-stimulating prosthesis’’. 115 It defined must be ‘‘useful for some purpose’’. 128 It should be noted,
utility as requiring that an invention ‘‘be operative and however, that in its section on subject-matter, the
have some commercial value’’. 116 After stating that ‘‘[t]he MOPOP requires an art, process or manner of manufac-
utility of a patent may be proven by the reception ture to ‘‘produce an essentially economic result in rela-
received from the public’’, the Court found that the tion to trade, commerce, or industry’’. 129 Not only does
utility requirement was met as the invention had com- this relate to the issue of whether an invention is patent-
































































ESTs under Canadian Patent Law: Useful or Not? 79
but it also does not apply to compositions of matter. forensic identification. 137 The use of ESTs as research
Thus, under the MOPOP, there is no general require- tools accelerates research and development, and saves
ment that inventions have either commercial utility or important resources in terms of time and cost. They
industrial value. therefore provide an economic benefit to those who use
them, and are of sufficient value to the scientific commu-An examination of the above cases reveals that the
nity to meet the test set out in Re McIntyre. 138type of utility that is required for inventions to meet the
requirement under the law is somewhat ambiguous. Utility is meant to be an easy test to meet. 139 As
Canadian courts have not, to date, required that inven- such, it should be flexible enough to take into account
tions have a specific, substantial and credible utility, as is the fact that not all inventions are intended to produce
required in the United States. Rather, they have used marketable products available to the purchasing public.
expressions such as ‘‘commercial utility’’, ‘‘commercial Certain inventions are meant to be used by a particular
success’’, ‘‘commercial value’’ and ‘‘industrial value’’, trade or industry, without necessarily becoming objects
sometimes interchangeably, and mostly without any of commerce. According to the Supreme Court decision
explanation of their meaning. Courts have also referred in Consolboard, all that is required of an invention is
to similar expressions in their examination of whether that it ‘‘be useful for some purpose’’. 140 As such, the use
an invention meets the requirement of inventiveness. 130 of ESTs as research tools should be sufficient to meet this
The uncertainty surrounding the meaning of utility as low standard. In fact, not only do ESTs ‘‘have the poten-
required by the Patent Act makes it difficult to ascertain tial to yield commercial products in the future’’, 141 but
how it would be applied to ESTs, and whether such they can also be sold as commercial products, even for
‘‘inventions’’ will be found to satisfy the requirement. their use as research tools. 142 As explained in The Ethics
of Patenting DNA, ‘‘[i]n general, owners of patents on
research tools may reali[z]e commercial value from their
Utility of ESTs patents either by licensing patents for particular
The patentability of ESTs raises a number of com- sequences. . .or by applying the knowledge within the
plex issues, one of which is whether such inventions institution to programmes aimed at discovering drugs, or
meet the requirement of utility under patent law. ESTs other research’’. 143
have been described as having little or no commercial Therefore, not only are ESTs valuable to the scien-
value, because ‘‘they do not themselves result in a tific community, and as such can be described as having
‘product’, but rather allow one to continue down the industrial utility, but they may also have ‘‘some’’ com-
path to a useful end result. . . . It is the gene itself, in its mercial value. If utility truly is an easy test to meet, and if
full-length or characterized form, that is potentially this test is to be applied in a way that takes into account
useful (in advancing a commercial interest or biological the particular community to which the invention is
knowledge)’’. 131 As such, because most ESTs have ‘‘no addressed, then ESTs are of sufficient scientific value to
genuine therapeutic or diagnostic value’’, their use, as meet the utility requirement under the law. The fact that
research tools, is considered intermediate. 132 While pro- the full-length gene may be of greater scientific interest
viding a means through which commercial products, and may have greater commercial value then a partial
such as medicines or vaccines, may be developed, ESTs sequence should not take away from the utility of ESTs
are generally not considered such products them- as research tools. In addition, I would suggest that ESTs
selves. 133 ESTs rarely provide specific information are beneficial to the public. While they may not provide
regarding the location and function of the full-length a marketable product, they provide an indirect benefit
gene, and a significant amount of work is needed to through quicker development and commercialization of
isolate the full-length gene and identify its function. 134 medicines, vaccines and diagnostic tests.
Although most ESTs may serve as probes or markers,
The utility requirement for patentability is an easytheir gene or chromosomal target is generally unknown
test to meet. Unfortunately, Canadian courts have notwhen patent protection is sought. 135
consistently interpreted and applied the requirement.
For the reasons that follow, I would suggest that This makes it difficult to know whether ESTs meet the
ESTs meet the current utility requirement under Cana- requirement under the law. Despite the uncertainty that
dian patent law. surrounds the application of the utility requirement, I
ESTs are important research tools that have a signifi- suggested, above, that ESTs useful as research tools meet
cant value to the scientific community, largely because the current test because they have value to the scientific
they ‘‘represent a copy of just the interesting part of the community and are beneficial to the public. As such,
genome, that which is expressed’’. 136 A DNA sequence they are useful ‘‘for some purpose’’, as required by the
can assist in isolating the full-length gene, which can MOPOP.
then be sequenced, characterized and its function identi-
fied. Various uses to which the biotechnology industry
The Doctrine of Sound Prediction can put ESTs include using them as diagnostic probes, to
construct arrays and perform comparative genomics In certain circumstances, the utility requirement can
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application. A sound prediction of utility can satisfy the The MOPOP also confirms that ‘‘a lucky guess or
requirement under the law. mere speculation’’ will not satisfy the requirements
under the doctrine. 157The doctrine of sound prediction was explained by
the Supreme Court of Canada in Apotex Inc. v. The doctrine of sound prediction has been applied
Wellcome Foundation Ltd. 144 In that case, the applicant in a number of cases to chemical compounds, the
had identified a new use for the known drug, AZT. The Supreme Court of Canada stating, in Monsanto, that
Court found that the utility requirement under s. 2 of ‘‘[w]e are no longer in the days when the architecture of
the Patent Act could ‘‘either be demonstrated or be a chemical compounds [is] a mystery. By means of modern
sound prediction based on the information and exper- techniques, chemists are now able to map out in detail
tise then available [at the date of application]’’. 145 After the exact composition of every atom in very complex
stating that the doctrine requires more than mere specu- molecules. . .. ’’ 158 To date, the doctrine has not been
lation, the Court set out its three components: applied to a case where patent protection was sought for
DNA sequences. Nevertheless, given that human genetic(1) a factual basis for the prediction;
material is treated like chemical compounds for the pur-(2) a sound line of reasoning from which the
poses of patent law,159 the doctrine should be equallydesired result can be inferred from the factual
applicable to such inventions.basis; and
An argument could be made that, in certain circum-(3) proper disclosure. 146
stances, patent protection could be extended beyond theThe Court found that the doctrine was applicable
simple EST sequence to include the full-length genein that case, as the applicant had ‘‘enough information
sequence or amino acid sequence, even if its exact func-about AZT and its activity against HIV in human cells to
tion and location on the human chromosome aremake a sound prediction that AZT would be useful in
unknown. There are situations in which it is possible tothe treatment and prophylaxis of HIV/AIDS in human
make a sound prediction as ‘‘to the identity or functionbeings’’. 147
of a gene from which an EST has been obtained’’. 160
The doctrine was first adopted into Canadian Law
As Resnik explains, ‘‘DNA contains information forin Monsanto Co. v. Canada (Commissioner of Pat-
the primary structure [amino acid sequence] of a pro-ents), 148 based on the English case of Olin Mathieson
tein’’. 161 This is particularly true of ESTs, since they con-Chemical Corp. v. Biorex Laboratories Ltd. 149 and the
tain only coding portions of DNA. ESTs which representCanadian case of Burton Parsons Chemical Inc. v. Hew-
the beginning portion of a gene (5’ ESTs), indicate thelett-Packard (Canada) Ltd. 150 The findings in Monsanto
correct reading frame, from which the amino acidwere subsequently applied by the Federal Court of
sequence can be determined.Appeal in Ciba-Geigy AG v. Commissioner of Patents,
where the Court was faced with an application for new An EST, which is generally about 400 to 500 nucle-
amines useful in the treatment of cancer. 151 The appli- otides in length, is sufficiently long to encode an amino
cant had not tested all of the amines before filing his acid domain. 162 A domain is a feature of the three
application. The Court stated that ‘‘[t]he predictability of dimensional shape of a protein, usually described in
a particular result seems to me to be essentially a ques- terms of its fold. 163 Because the conformation of proteins
tion of fact, though in some situations it may be a matter determines their role in the human body, and because
of common knowledge’’. 152 The doctrine was not appli- different protein domains act in a semi-independent
cable in that case, the Court finding that what is chemi- manner, proteins with similar domains usually have
cally predictable may not be pharmacologically predict- functions in common. 164 For example, a particular
able. 153 domain may indicate that the gene product will be a
The case law on sound prediction suggests that a catalytic enzyme.165
factual basis for a prediction can be supplied by tested Thus, the amino acid sequence of the resulting pro-compounds, and a sound line of reasoning can be tein can be determined based on the DNA sequence ofgrounded in the known ‘‘architecture of chemical com- an EST. Occasionally, the amino acid sequence willpounds’’. 154 There will be proper disclosure where a ‘‘full, encode a domain which is typical of a protein having aclean and exact description of the nature of the inven- certain type of function. On this basis, a sound predic-tion and the manner in which it can be practiced’’ is tion can be made with respect to the function of thedisclosed. 155 protein which is partly encoded by the EST.166 As evi-
The doctrine, as well as its three requirements, have denced from the Japan Patent Office Examination
been incorporated into the MOPOP: Guidelines, not all domains reveal a major function of
If utility of the subject matter which forms the basis of a the protein. 167 For example, an EST which encodes a
claim is not apparent or the promised utility of the subject glycosylation domain would not justify a claim for the
matter is in doubt, then the applicant must have established amino acid sequence, because glycoproteins have a wideutility, at the claim date, either by demonstration (i.e. testing
range of functions, even though they may also have cer-the invention and conclusively proving utility) or by sound
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When ESTs are sequenced, the practice is to enter to the scientific community, as research tools, to be con-
these sequences into an EST database (dbEST). 169 At this sidered ‘‘useful’’ under the law. The extent, to which the
point, one can compare the inputted sequence with doctrine of sound prediction could be applied to allow
those already in the database, allowing a determination patents for full-length genes or proteins, where only an
of whether the ESTs resemble a known gene, gene EST sequence is disclosed, remains an open question.
family, or category of gene function. 170 I would suggest Although Canadian courts and CIPO have not adopted
that this, too, can be the basis of sound prediction. the United States approach for assessing the utility of an
For the reasons provided above, I would suggest that invention, federal and provincial government reports
if a sound prediction can be made of the function of the have been calling upon CIPO to ‘‘develop interpretive
gene or protein based on the DNA sequence, which guidelines for the application of patentability criteria to
reveals information about structure, the utility require- genetic innovations, similar to those in the United States
ment could be satisfied. The fact that this function may for applying the utility criterion to [human genetic
have been identified through a homology search in a materials]’’. 176 CIPO is currently updating the chapter of
computer database is irrelevant to the determination of the MOPOP which deals with the utility requirement for
whether or not the utility requirement is met. The patentability. This may clarify its position regarding the
MOPOP confirms that sound prediction can be based patentability of ESTs, and more specifically, may reveal
on the structure of a molecule. 171 whether research tools meet this requirement. Regardless
of the position adopted by CIPO, we could expect litiga-The United States, Japan and the European Union
tion to arise, calling upon the courts to address the issueshave acknowledged that the utility requirement can be
associated with the patentability of ESTs. Given that twomet where the function of a gene can be inferred from
of the leading jurisdictions in patent policy, the Unitedthe sequence of a DNA fragment through computer
States and Japan, 177 have clearly adopted a commoncomparisons with other inputted sequences producing
approach, Canadian courts may well decide to endorsehigh homology. 172 While it is not quite clear what high
this approach as well. Should they decide to do so, only ahomology consists of, the Japan Patent Office Examina-
limited number of ESTs would meet the utility require-tion Guidelines indicate that a 20-30% homology would
ment under Canadian patent law.be insufficient to claim that the DNA fragment for
which a patent is being sought has a function similar or An examination of the threshold requirement of
akin to another known sequence. 173 patentable subject- matter and the patentability require-
ments of novelty and non-obviousness was beyond theGiven that the Supreme Court in Apotex warned
scope of this article, as was a discussion of the moralagainst confusing sound prediction with speculation, 174
concerns associated with DNA patenting and the poten-the extent to which the doctrine may be applied to
tial impact on research and innovation from allowingbroaden the scope of patent protection for ESTs, is as of
patents on research tools such as ESTs. 178 The debateyet unclear.
over the patentability of DNA is not limited to the ques-
tion of utility, and Canadian courts may ultimately
decide the issue on the basis of one of the other require-Conclusion 
ments.
he patenting of human genetic material, in partic-
I would like to conclude by suggesting two reasonsT ular ESTs, has been the subject of debate for a
why the utility criterion for patentability has proven sonumber of years. Because most ESTs are useful only as
difficult to apply to human genetic material.molecular probes or markers for the identification of the
First, there is no consistency in the way in whichcorresponding full-length gene, the debate has largely
courts, patent offices and academics describe the kind offocused on whether ESTs meet the utility requirement
utility that is required for biotechnological inventions.for a patent. It is now recognized that ‘‘there is no
Under certain interpretations, a DNA sequence itselfstraightforward legal reason to deny patent protection to
must have a function, apart from that of the full-lengthall ESTs’’. 175 The United States, and a number of other
gene. Under others, something must be known aboutjurisdictions, have adopted a similar approach, according
the full-length gene or protein. For example, the CBACto which this requirement will be met where an inven-
Report states that ‘‘to obtain a patent, the inventor musttion has specific, substantial and credible utility.
be able to identify or modify the novel genetic sequenceA number of applications have been filed with CIPO for
and specify the product of the sequence and how itpatents on ESTs and other human genetic materials. It is
functions in nature’’. 179 Considering that it is possible fornot clear whether ESTs meet the utility requirement
a DNA sequence to have a specific function apart fromunder Canadian patent law. Court and administrative
that of the full-length gene, why should the inventor bebody decisions have inconsistently described this
required to have determined the product of therequirement, referring to such expressions as ‘‘commer-
sequence before applying for a patent?cial utility’’ and ‘‘industrial value’’, without providing an
explanation of their meaning. ESTs, while arguably Secondly, there is significant confusion with respect
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issued for a DNA sequence. It is not clear when knowl- over ‘‘every use of which his invention is susceptible,
edge of a DNA sequence should permit patent protec- whether such use is known or unknown to him’’. 180 Not
tion for the full-length gene or protein, and whether a only can an EST have multiple functions, but so can the
patent for use as a probe or marker should cover all full-length gene. 181
other uses. Usually, an inventor is entitled to protection
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